Q-omics provides the consensus-scored RSPO1 profile across patient tissues and cancer cell-line models. RSPO1 expression is associated with patient survival in 28 of 34 cancer types, with the highest sampling consensus in HNSC. Among the 18 cancer types available for tumor–normal comparison, RSPO1 is differentially expressed in 15, with the highest sampling consensus in HNSC. Additionally, RSPO1 RNA expression shows 17,042 significant protein co-abundance associations, with the highest sampling consensus in LUAD. Together, these results highlight HNSC, and LUAD as cancer lineages where RSPO1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for RSPO1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes RSPO1 survival associations across molecular data types. RSPO1 RNA expression shows survival associations in the most cancer types (28), followed by mutation status (5) and mass-spec protein abundance (1). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible RSPO1 RNA expression–survival associations across cancer types. High RSPO1 expression shows unfavorable associations in KIRP and ACC, but favorable associations in HNSC, MESO, LUAD and ESCA. The HNSC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify HNSC as the clearest survival context for RSPO1 RNA expression.
This table summarizes RSPO1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 15. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for RSPO1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. RSPO1 shows lower tumor expression in HNSC, KIRC, COAD, LUSC, LUAD and KICH. The HNSC box plot shows higher RSPO1 RNA expression in normal versus tumor tissue (log2 FC = −1.067, t-test p < 0.001).
This table shows molecular features associated with RSPO1 in patient tissues and cancer cell lines. In patient samples, RSPO1 shows the broadest associations at the RNA and protein expression levels, with LUAD recurring as the lineage with the largest associated feature set. In cancer cell lines, RSPO1 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in OVARY, while CRISPR and shRNA rows add functional-dependency signals in BONE and LUNG_NSCLC_LUAD.
